{"id":521764,"date":"2021-08-03T01:03:03","date_gmt":"2021-08-03T05:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/"},"modified":"2021-08-03T01:03:03","modified_gmt":"2021-08-03T05:03:03","slug":"sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/","title":{"rendered":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development"},"content":{"rendered":"
\n

\n — Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas —<\/em>
\n \n <\/p>\n

\n — Fast tracks establishment of Sanofi\u2019s recently announced\u00a0<\/em>
\n mRNA Center of Excellence —<\/em>\n <\/p>\n

\n — Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology —<\/em>\n <\/p>\n

PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — As part of Sanofi\u2019s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.<\/p>\n

\u201cTranslate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,\u201d said Paul Hudson, Sanofi Chief Executive Officer. \u201cA fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space. We will also be able to accelerate our existing partnered programs already under development. Our goal is to unlock the potential of mRNA in other strategic areas such as immunology, oncology, and rare diseases in addition to vaccines.\u201d<\/p>\n

\u201cSanofi and Translate Bio have a shared commitment to innovation in the mRNA space. With Sanofi\u2019s long-standing expertise in developing and commercializing vaccines and other innovative medicines on a global scale, Translate Bio\u2019s mRNA technology is now even better positioned to reach more people, faster,\u201d said Ronald Renaud, Chief Executive Officer, Translate Bio. \u201cThe talented and dedicated Translate Bio team has built the foundation of a strong mRNA platform. Our expertise coupled with that of Sanofi has driven significant progress under the collaboration thus far, and we believe that this acquisition will strengthen the team\u2019s ability to achieve the full potential of the mRNA technology.\u201d<\/p>\n

In June 2018, Sanofi and Translate Bio entered into a collaboration and exclusive license agreement to develop mRNA vaccines which was further expanded in 2020 to broadly address current and future infectious diseases. There are two ongoing mRNA vaccine clinical trials under the collaboration, the COVID-19 vaccine Phase 1\/2 study with results expected in Q3 2021 and the mRNA seasonal influenza vaccine Phase 1 trial with results due in Q4 2021. The acquisition builds on Sanofi\u2019s establishment of a first-of-its kind vaccines mRNA Center of Excellence.<\/p>\n

On the therapeutic side, Translate Bio has an early-stage pipeline in cystic fibrosis and other rare pulmonary diseases. In addition, discovery work is ongoing in diseases that affect the liver, and Translate Bio\u2019s MRTTM<\/sup> platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as oncology. Sanofi\u2019s recent acquisition of Tidal Therapeutics expanded the company\u2019s mRNA research capabilities in both immuno-oncology and inflammatory diseases. The Translate Bio acquisition further accelerates Sanofi\u2019s efforts to develop transformative medicines using mRNA technology.<\/p>\n

\n Transaction Terms<\/strong>\n <\/p>\n

Under the terms of the merger agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of Translate Bio common stock for $38.00 per share in cash reflecting a total equity value of Translate Bio of approximately $3.2 billion. The purchase price represents a premium of 56% to Translate Bio\u2019s volume-weighted average price per share over the past 60 days.<\/p>\n

To demonstrate their commitment to the transaction, the chief executive officer of Translate Bio and Translate Bio\u2019s largest shareholder, The Baupost Group, L.L.C., have signed binding commitments to support the tender offer. These binding commitments, combined with the Translate Bio shares already owned by Sanofi or its affiliates, represent a total of approximately 30% of Translate Bio\u2019s total shares outstanding.<\/p>\n

The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Translate Bio common stock that together with shares already owned by Sanofi or its affiliates represents at least a majority of the outstanding shares of Translate Bio common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of Sanofi will merge with Translate Bio and the outstanding Translate Bio shares not already owned by Sanofi or its affiliates that are not tendered in the tender offer will be converted into the right to receive the same $38.00 per share in cash paid in the tender offer. The tender offer is expected to commence later this month. Sanofi plans to fund the transaction with available cash resources. Subject to the satisfaction or waiver of customary closing conditions, Sanofi expects to complete the acquisition in the third quarter of 2021.<\/p>\n

Morgan Stanley & Co. International plc is acting as exclusive financial advisor to Sanofi while Weil, Gotshal & Manges LLP is acting as legal counsel. Centerview Partners is acting as lead financial advisor to Translate Bio in the transaction, while Paul, Weiss, Rifkind, Wharton & Garrison LLP is acting as legal counsel. Evercore is also acting as a financial advisor in this transaction to Translate Bio. MTS Health Partners, LP is also giving financial advice to Translate Bio.<\/p>\n

\n About Translate Bio<\/strong>
\n
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis in a Phase 1\/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes it technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies and protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.<\/p>\n

\n About Sanofi<\/strong>
\n
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.<\/p>\n

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.<\/p>\n

\n Sanofi Media Relations Contacts<\/strong>
\n
Ashleigh Koss
Tel: +1 (908) 205-2572
Ashleigh.Koss@sanofi.com<\/a><\/p>\n

Sandrine Guendoul
Tel.: +33 (0)6 25 09 14 25
Sandrine.Guendoul@sanofi.com<\/a><\/p>\n

\n Sanofi Investor Relations Contacts Paris<\/strong>
\n
Eva Schaefer-Jansen
Arnaud Delepine
Nathalie Pham<\/p>\n

\n Sanofi Investor Relations Contacts North America<\/strong>
\n
Felix Lauscher
Fara Berkowitz
Suzanne Greco<\/p>\n

Tel.: +33 (0)1 53 77 45 45
investor.relations@sanofi.com<\/a><\/p>\n

\n https:\/\/www.sanofi.com\/en\/investors\/contact<\/a>\n <\/p>\n

\n Translate Bio Media Relations Contact<\/strong>
\n
Maura Gavaghan
mgavaghan@translate.bio<\/a><\/p>\n

\n Translate Bio Investor Relations Contact<\/strong>
\n
Teri Dahlman
tdahlman@translate.bio<\/a><\/p>\n

\n
\n Sanofi and Translate Bio Forward-Looking Statements<\/em>
\n <\/strong>
\n
\n This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words \u201cexpects\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cintends\u201d, \u201cestimates\u201d, \u201cplans\u201d, \u201cwill be\u201d and similar expressions. Although Sanofi\u2019s and Translate Bio \u2019s management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi and Translate Bio, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Sanofi\u2019s and Translate Bio\u2019s ability to complete the acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers, suppliers or patient groups, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Sanofi\u2019s shares could decline, as well as other risks related Sanofi\u2019s and Translate Bio\u2019s respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the FDA or the EMA, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi\u2019s ability to benefit from external growth opportunities and to complete related transactions and\/or obtain regulatory clearances, risks associated with Sanofi\u2019s and Translate Bio\u2019s intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on Sanofi and Translate Bio and their respective customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on Sanofi\u2019s and Translate Bio\u2019s employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact Sanofi and Translate Bio. This situation is changing rapidly and additional impacts may arise of which Sanofi and Translate Bio are not currently aware and may exacerbate other previously identified risks. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on companies\u2019 consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) made by Sanofi and Translate Bio and the public filings with the AMF made by Sanofi, including those listed under \u201cRisk Factors\u201d and \u201cCautionary Statement Regarding Forward-Looking Statements\u201d in Sanofi\u2019s annual report on Form 20-F for the year ended December 31, 2020, and Translate Bio\u2019s annual report on Form 10-K for the year ended December 31, 2020, quarterly reports on Form 10-Q and current reports on Form 8-K filed with the SEC. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Sanofi and Translate Bio do not undertake any obligation to update or revise any forward-looking information or statements.<\/em>\n <\/p>\n

\n
\n Additional Information for US shareholders<\/em>
\n <\/strong>
\n
\n The tender offer for the outstanding shares of Translate Bio common stock referenced in this press release has not yet commenced. This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Sanofi and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Sanofi and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Translate Bio will file a Solicitation\/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION\/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. TRANSLATE BIO STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF TRANSLATE BIO SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation\/Recommendation Statement, will be made available to all holders of Translate Bio stock at no expense to them. The tender offer materials and the Solicitation\/Recommendation Statement will be made available for free at the SEC\u2019s website at www.sec.gov. Additional copies may be obtained for free by contacting Sanofi or Translate Bio. Copies of the documents filed with the SEC by Translate Bio will be available free of charge on Translate Bio\u2019s internet website at<\/em>
\n
\n www.translate.bio<\/u>
\n <\/em>
\n or by contacting Translate Bio\u2019s Investor Relations Department at tdahlman@translate.bio. Copies of the documents filed with the SEC by Sanofi will be available free of charge on Sanofi\u2019s internet website at https:\/\/www.sanofi.com\/en\/investors or by contacting Sanofi\u2019s Investor Relations Department at investor.relations@sanofi.com. <\/em>\n <\/p>\n

\n In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation\/Recommendation Statement, Sanofi files annual and special reports and other information with the SEC and Translate Bio files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Sanofi and Translate Bio at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. Sanofi\u2019s and Translate Bio\u2019s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.<\/em>\n <\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

— Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas — — Fast tracks establishment of Sanofi\u2019s recently announced\u00a0 mRNA Center of Excellence — — Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology — PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — As part of Sanofi\u2019s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 … <\/p>\n

Continue reading “Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521764","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"— Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas — — Fast tracks establishment of Sanofi\u2019s recently announced\u00a0 mRNA Center of Excellence — — Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology — PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — As part of Sanofi\u2019s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 … Continue reading "Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T05:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development\",\"datePublished\":\"2021-08-03T05:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/\"},\"wordCount\":2477,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/\",\"name\":\"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=\",\"datePublished\":\"2021-08-03T05:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/","og_locale":"en_US","og_type":"article","og_title":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development - Market Newsdesk","og_description":"— Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas — — Fast tracks establishment of Sanofi\u2019s recently announced\u00a0 mRNA Center of Excellence — — Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology — PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — As part of Sanofi\u2019s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 … Continue reading \"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T05:03:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development","datePublished":"2021-08-03T05:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/"},"wordCount":2477,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/","name":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=","datePublished":"2021-08-03T05:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ5MyM0MzM3ODIwIzIxMTA0OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521764"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521764\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}